Key Developments: Eisai Co Ltd (4523.T)

4523.T on Tokyo Stock Exchange

4,571JPY
1:00am EST
Price Change (% chg)

¥106 (+2.36%)
Prev Close
¥4,466
Open
¥4,522
Day's High
¥4,573
Day's Low
¥4,487
Volume
2,494,800
Avg. Vol
1,780,353
52-wk High
¥5,039
52-wk Low
¥3,694

Search Stocks

Latest Key Developments (Source: Significant Developments)

Eisai and Kyorin Holdings Inc's subsidiary enters into agreement concerning evaluation and use of Eisai’s compound library
Thursday, 9 Oct 2014 09:30pm EDT 

Kyorin Holdings Inc:Says Eisai and Kyorin Pharmaceutical, wholly owned subsidiary of the company entered into an agreement concerning evaluation and use of Eisai’s compound library, which includes natural products, by subsidiary for discovery of innovative new antibacterial agents.Eisai grants subsidiary the rights to evaluate the feasibility of developing compounds for the antibacterial field using the compound library owned by Eisai, and Eisai receives a certain lump-sum payment from subsidiary.In addition, in case that a license agreement is concluded in the future based on the terms of this agreement, subsidiary will receive the exclusive rights to research, develop, manufacture and market a compound(s) as an antibacterial agent in Japan.  Full Article

Eisai Co Ltd's Eisai Inc sells U.S. rights to Zonegran (zonisamide) Capsules to Concordia Pharmaceuticals Inc.
Wednesday, 3 Sep 2014 07:00am EDT 

Eisai Inc:Says enters into agreement with Concordia Pharmaceuticals Inc., a subsidiary of Concordia Healthcare Corp., to purchase Eisai's U.S. and Puerto Rican commercialization and distribution rights to Zonegran.Says as part of deal terms, Eisai will receive full payment from Concordia upon closing.Saysin addition, Eisai and Concordia are expected to enter into a supply agreement under which Eisai will serve as Concordia's supplier of Zonegran for the U.S. and Puerto Rican markets.  Full Article

Eisai Co Ltd and Zeria Pharmaceutical concludes license agreement concerning E3710
Monday, 18 Aug 2014 01:00am EDT 

Eisai Co Ltd:Says Eisai and Zeria Pharmaceutical concluded a license agreement concerning E3710, a novel proton pump inhibitor (PPI) discovered and developed in-house by Eisai.Eisai will grant Zeria the exclusive rights to develop and co-promote, and the non-exclusive right to manufacture, E3710 in Japan.Eisai will receive down payment and additional royalties from Zeria, and after marketing authorization has been successfully obtained, Eisai will pay Zeria a certain consideration.Zeria will develop E3710 and work to obtain marketing authorization, the two companies will collaborate on marketing E3710 after launch.  Full Article

R&I affirms Eisai Co Ltd's rating at "AA-" and announces negative outlook
Monday, 28 Jul 2014 02:00am EDT 

Eisai Co Ltd:Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "AA-".Rating outlook negative, changed from stable.  Full Article

NanoCarrier Co Ltd announces exclusive license agreement with Eisai Co., Ltd
Monday, 23 Jun 2014 02:00am EDT 

NanoCarrier Co Ltd:Reached a world-wide, exclusive license agreement, which allows NanoCarrier to obtain rights to develop, sell and market an active compound called E7974 for new drug development, which is owned and has been being developed by Eisai with Eisai.NanoCarrier will start research and development activities, including clinical trials, in order to develop micelle-based drugs encapsulating E7974 as an active compound.  Full Article

Eisai Co Ltd's Eisai Inc announces phase III trial with Antiepileptic Drug Perampanel meets primary endpoint
Monday, 16 Jun 2014 10:05pm EDT 

Eisai Inc:Says a phase III clinical trial (study 332) of its in-house-discovered AMPA receptor antagonist perampanel has met its primary endpoint in patients with primary generalized tonic-clonic (PGTC) seizures, a severe form of seizures.An analysis of the trial data demonstrates that perampanel met its primary efficacy endpoint (reduction in seizure frequency per 28 days).The most frequently reported adverse events in this trial (>10 pct in the perampanel arm and greater than placebo) were dizziness, fatigue, headache, irritability and somnolence.Eisai Inc is a U.S. pharmaceutical subsidiary of Eisai Co., Ltd.  Full Article

Eisai announces application of IFRS
Tuesday, 25 Mar 2014 02:30am EDT 

Eisai Co Ltd:To apply International Financial Reporting Standards (IFRS) as the new accounting method, to replace the current Japan Accounting Standards, starting from the financial report for first quarter of fiscal year ending March 2015.  Full Article

Eisai Co Ltd collaborates with Liverpool School of Tropical Medicine And University of Liverpool
Thursday, 20 Mar 2014 09:50am EDT 

Eisai Co Ltd:Enters collaboration with Liverpool School of Tropical Medicine and University of Liverpool to jointly identify new drugs effective against lymphatic filariasis and onchocerciasis (river blindness), both major types of filariasis.  Full Article

Eisai Co Ltd and Biogen Idec enter collaboration to develop and commercialize alzheimer's disease treatments
Wednesday, 5 Mar 2014 02:00am EST 

Eisai Co Ltd:Eisai Co Ltd and Biogen Idec entered into collaboration to develop and commercialize two of Eisai's clinical candidates for Alzheimer's disease (AD), E2609 and BAN2401.Agreement also provides Eisai with option to jointly develop and commercialize two of Biogen Idec's candidates for AD, anti-amyloid beta (Aβ) antibody BIIB037 and anti-tau monoclonal antibody.Both companies will share overall costs, including research and development expenses, with Eisai booking all sales for E2609 and BAN2401 and with profits to be split between the companies.Biogen Idec will provide Eisai with an upfront payment and a fixed amount of development, approval and commercial milestone payments.  Full Article

Eisai Co Ltd announces initiation of phase 3 trial of Eribulin Mesylate Injection Versus Weekly Paclitaxel in first and second lines of metastatic breast cancer
Thursday, 27 Feb 2014 08:15am EST 

Eisai Co Ltd:Start of randomized Phase 3 trial to compare the efficacy, safety and tolerability of eribulin mesylate to standard weekly paclitaxel as a first- or second line treatment for HER2-negative locally recurrent or metastatic breast cancer (MBC).Recruitment is active for this multicenter study, conducted in partnership with the Academic and Community Cancer Research United (ACCRU) group.Aims to enroll about 910 patients across the U.S. the primary endpoint is overall survival.Research study involves an investigational use of eribulin mesylate.Efficacy and safety of eribulin mesylate in first- and second-line MBC have not been established and this release is not intended to convey conclusions of efficacy and safety.  Full Article

BRIEF-Oncodesign enters into services agreement with Eisai

* Says it has entered into a services agreement with Eisai to develop a new personalized medicine program in earlier line metastatic breast cancer treatment

Search Stocks